Meridian Bioscience Inc

Meridian Bioscience — Q4 FY2021 Earnings Presentation

17 slides from Meridian Bioscience's earnings presentation, Nov 12, 2021

  1. Slide 1: FY2021 Q4 Results

    FY2021 Q4 Results November 12, 2021 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A

  3. Slide 3: Non-GAAP Financial Measures

    Certain financial measures presented in this presentation, such as operating expenses, operating income, operating margin, net earnings and net earnings per diluted share, each on an adjusted basis, excluding as applicable the effects of certain acquisition-related costs, changes in fair value of ac

  4. Slide 4: Q4 FY2021 Business Highlights

    Launched Air-Dryable™ sample specific master mixes for stool, blood and urine and Air-Dryable™ LAMP Mix for isothermal amplification Received U.S. design patent for Revogene® PIE (Fluidic Centripetal Device) Launched new environmentally friendly, REACH compliant, enzymes Closed $20M acquisition of t

  5. Slide 5: Fourth Quarter Earnings Summary

    FY2021 Fourth Quarter Earnings Summary ($000’s except Per Share Amounts) Adjusted (Non-GAAP) FY2021 FY2020 Change Net revenues $76,204 $64,153 +19% Gross margin % 59% 60% -1 pts Operating expenses(1) Ratio $31,432 41% $26,302 41% +20% -- pts Operating income Margin % $13,285 17% $12,029 19% +10% -2

  6. Slide 6: Fourth Quarter Operating Segment Highlights

    FY2021 Fourth Quarter Operating Segment Highlights ($000’s) Diagnostics segment (Adjusted Non-GAAP) FY2021 FY2020 Change Net revenues $34,301 $29,801 +15% Operating income / (loss) Margin % ($7,201) NMF ($2,515) NMF NMF NMF Diagnostics segment net revenues by: Technology: Molecular assays $5,671 $4,

  7. Slide 7: FY2021 Business Highlights

    Disrupted molecular reagents market with complete line of Air-Dryable™ master mixes optimized for specific sample types Submitted Curian® Campy 510(k) and Revogene® COVID-19 EUA Awarded $6.5M in RADx grants for the Revogene® COVID-19 assay Closed $20M acquisition of the BreathTek® Urea Breath Test F

  8. Slide 8: Full Year Earnings Summary

    FY2021 Full Year Earnings Summary ($000’s except Per Share Amounts) Adjusted (Non-GAAP) FY2021 FY2020 Change Net revenues $317,896 $253,667 +25% Gross margin % 63% 62% +1 pts Operating expenses(1) Ratio $105,828 33% $94,560 37% +12% -4 pts Operating income Margin % $95,320 30% $61,688 24% +55% +6 pt

  9. Slide 9: Full Year Operating Segment Highlights

    FY2021 Full Year Operating Segment Highlights ($000’s) Diagnostics segment (Adjusted Non-GAAP) FY2021 FY2020 Change Net revenues $127,760 $121,132 +5% Operating income / (loss) Margin % ($8,657) NMF $1,969 2% NMF NMF Diagnostics segment net revenues by: Technology: Molecular assays $19,037 $21,907 -

  10. Slide 10: Full Year COVID-19 Product Contribution

    FY2021 Full Year COVID-19 Product Contribution ($000’s) Life Science Q1 Q2 Q3 Q4 FY2021 FY2020 COVID-19 reagents revenue $42,500 $31,400 $14,700 $23,300 $111,900 $71,500 % of Total Life Science Revenue 68% 59% 45% 56% 59% 54% Life Science COVID-19 revenue by: Technology: Molecular reagents $33,850 $

  11. Slide 11: FY2022 Fiscal Year Guidance

    FY2022 Fiscal Year Guidance Meridian Bioscience Diagnostics Life Science Consolidated net revenues: $285 to $300 million Adjusted operating margin: 21% to 22% Tax Rate: 23.5% Adjusted net earnings per share*: $0.98 to $1.08 Net revenues: $145 to $150 million Net revenues: $140 to $150 million * Assu

  12. Slide 12: Meridian Growth Trends

    Meridian Growth Trends ($ in millions) Net Revenues Cash from Operations Life Science Diagnostics Reflects the mid-point of the guidance range for illustrative purposes Illustrative, not to scale (1) (2)

  13. Slide 13: Diagnostics R&D Pipeline

    Diagnostics R&D Pipeline (as of 9/30/2021) Breath Immunoassay Molecular Blood Chemistry Feasibility Development Clinicals FDA Liver MBT PMA C. difficile Shiga Toxin Streptococcus pneumoniae / Legionella RI Panel GI Panel COVID-19 EUA(1) PediaStat Analyzer Lead Expected FY22 FDA Submissions Shiga Tox

  14. Slide 14: Revogene PIE Patent

    Revogene PIE Patent U.S. Patent No. 11,123,730 Fluidic Centripetal Device Patent is for our proprietary PIE system (referred to as a Fluidic Centripetal Device) used on the Revogene platform, allowing for testing biological material in a fluid The apparatus comprises a fluidic component layer having

  15. Slide 15: Life Science FY22 Product Pipeline

    Life Science FY22 Product Pipeline Sample specific master mixes for Lyo-Ready and Isothermal Amplification (incl LAMP) New thermostable, bifunctional enzymes for qPCR New NGS enzymes for handheld sequencing devices New immunological products for infectious disease

  16. Slide 16: Life Science Major Customers

    Life Science Major Customers Number of Major Industry Customers(1) (% of total Life Science Net Revenues) ~75% ~30% Registered Assay Diversity(2) (% of total Major Industry Customers) IVD Customers generating $1M+ in net revenues in select year, excludes academic, research, resellers and distributor

  17. Slide 17: Contact

    Contact: mbi@meridianbioscience.com

Meridian Bioscience — Q4 FY2021 Earnings Presentation on 6ix